Gnubiotics Sciences is a Swiss-based biotech developing next generation human milk oligosaccharides (HMOs), composed of up to 130 different microbiota-accessible carbohydrates (MACs) for the global infant formula market. Atthe 51st annual conference ofthe European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN), Gnubiotics presented the first structural and functional data about their product, the naturally-occurring MACs. These MACs, of superior diversity relative to the recently launched synthetic HMOs, 2-fucosyllactose (2FL) and lacto-N-neotetraose (LNnT), can be selectively utilized by specific bacteria present in the infant’s microbiome. The Gnubiotics’ team also presented their state-of-the-art analytical capabilities by showing at the strain level, changes to the infant’s Bifidobacterial composition as well as a highresolution profiling of Bacteroides species and strains in caesarean and vaginally born infants.

Press release